0354 GMT - The potential for US$50 million in cost synergies jumps out at UBS analysts as a key attraction of Telix Pharmaceuticals' US$2.35 billion acquisition of isotope manufacturer ITM. The analysts, who have a last-published buy rating on Telix's Australia-listed stock, tell clients in a note that the vertical integration of Telix with a supplier of key therapeutic isotopes strengthens its platform. They point out that ITM sits within a commercially validated category, with global annual sales of US$800 million for approved somatostatin receptor-targeted radioligand therapies. UBS has a target price of 22.00 Australian dollars on the stock, which is down 5.4% at A$16.88.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.